UBX Unity Biotechnology, Inc. revenue, earnings and financials
For the quarter ended March 31, 2025, Unity Biotechnology, Inc. reported revenue of $0, net income of −$7.30M and diluted EPS of −$0.43; for the fiscal year ended December 2024 revenue was $0.
UBX annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$31.2M, net income −$26.0M (margin n/a), EPS −$1.54
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$44.7M, net income −$39.9M (margin n/a), EPS −$2.70
- Fiscal year ended Dec 2022: revenue $236K, gross profit n/a, operating income −$57.6M, net income −$44.5M (margin -18842.8%), EPS −$4.68
- Fiscal year ended Dec 2021: revenue $4.78M, gross profit n/a, operating income −$56.7M, net income −$60.7M (margin -1269.3%), EPS −$10.88
UBX quarterly revenue and earnings
- Quarter ended Mar 31, 2025: revenue $0, net income −$7.30M, EPS −$0.43
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$8.44M, EPS −$0.51
- Quarter ended Sep 30, 2024: revenue n/a, net income −$6.48M, EPS −$0.38
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.28M, EPS −$0.31
- Quarter ended Mar 31, 2024: revenue $0, net income −$5.79M, EPS −$0.34
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$4.34M, EPS −$0.25
- Quarter ended Sep 30, 2023: revenue n/a, net income −$14.8M, EPS −$1.01
- Quarter ended Jun 30, 2023: revenue $0 (down 100.0% year over year), net income −$15.5M, EPS −$1.07
- Quarter ended Mar 31, 2023: revenue $0, net income −$5.28M, EPS −$0.37
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0 (down 100.0% year over year), net income −$7.42M, EPS $0.52
- Quarter ended Sep 30, 2022: revenue $0, net income −$5.00M, EPS −$0.50
- Quarter ended Jun 30, 2022: revenue $236K, net income −$13.1M, EPS −$1.90
- Quarter ended Mar 31, 2022: revenue $0, net income −$18.9M, EPS −$2.80
- Quarter ended Dec 31, 2021 (from the annual report): revenue $4.78M, net income −$10.7M, EPS −$7.30
- Quarter ended Sep 30, 2021: revenue $0, net income −$16.5M, EPS −$2.97
- Quarter ended Jun 30, 2021: revenue $0, net income −$17.8M, EPS −$0.32
- Quarter ended Mar 31, 2021: revenue $0, net income −$15.8M, EPS −$0.29
UBX cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$20.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$37.1M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$52.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$45.1M, share buybacks n/a
UBX balance sheet
- Mar 31, 2025: cash $8.00M, total assets $30.3M, total liabilities $30.6M, shareholders' equity −$205K
- Dec 31, 2024: cash $7.58M, total assets $37.7M, total liabilities $31.2M, shareholders' equity $6.49M
- Sep 30, 2024: cash $8.90M, total assets $47.1M, total liabilities $33.0M, shareholders' equity $14.1M
- Jun 30, 2024: cash $7.58M, total assets $53.5M, total liabilities $33.8M, shareholders' equity $19.8M
- Mar 31, 2024: cash $7.43M, total assets $58.9M, total liabilities $34.9M, shareholders' equity $24.0M
- Dec 31, 2023: cash $19.8M, total assets $65.7M, total liabilities $37.3M, shareholders' equity $28.4M, long-term debt $0
- Sep 30, 2023: cash $7.88M, total assets $69.3M, total liabilities $41.5M, shareholders' equity $27.7M, long-term debt $0
- Jun 30, 2023: cash $19.1M, total assets $101M, total liabilities $60.2M, shareholders' equity $40.8M, long-term debt $4.07M
What is UBX's revenue?
Unity Biotechnology, Inc. reported $0 of revenue for the fiscal year ended December 2024.
Is UBX profitable?
No. Unity Biotechnology, Inc. lost $27.5M over the last four quarters.
What is UBX's EPS?
Diluted earnings per share over the last four quarters were −$1.63; −$0.43 in the latest quarter.